



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Director’s Shareholding

London: Monday, 15 December 2008: Chi-Med was informed on 12 December 2008 that Mr Christian Hogg, Executive Director and Chief Executive Officer of Chi-Med, purchased 100,000 ordinary shares of US\$1.00 each in Chi-Med (the “Shares”) at a price of 40p each on 12 December 2008.

Following this purchase, Mr Hogg is beneficially interested in 270,000 Shares, representing approximately 0.5% of the current issued share capital of Chi-Med. This is in addition to the 576,136 vested options held by him, representing approximately 1.1% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med
Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson
Anthony Carlisle
David Dible

Telephone: +44 (0) 20 7638 9571
+44 (0) 7973 611 888
+44 (0) 7967 566 919

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.